Development of Inactivated FAKHRAVAC<sup>®</sup> Vaccine against SARS-CoV-2 Virus: Preclinical Study in Animal Models

The recent viral infection disease pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global public health crisis. Iran, as one of the countries that reported over five million infected cases by September 2021, has been concerned with the urgent devel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Soheil Ghasemi, Kosar Naderi Saffar, Firooz Ebrahimi, Pezhman Khatami, Arina Monazah, Ghorban-Ali Alizadeh, Hossein-Ali Ettehadi, Iman Rad, Shahrzad Nojehdehi, Mousa Kehtari, Fatemeh Kouhkan, Hesam Barjasteh, Sohrab Moradi, Mohammad-Hosein Ghorbani, Ali Khodaie, Moslem Papizadeh, Roghayeh Najafi, Ehsan Naghneh, Davood Sadeghi, Ahmad Karimi Rahjerdi
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
R
Acceso en línea:https://doaj.org/article/4029ad1958be4e4ea152650fa4f5f074
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The recent viral infection disease pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global public health crisis. Iran, as one of the countries that reported over five million infected cases by September 2021, has been concerned with the urgent development of effective vaccines against SARS-CoV-2. In this paper, we report the results of a study on potency and safety of an inactivated SARS-CoV-2 vaccine candidate (FAKHRAVAC) in a preclinical study so as to confirm its potential for further clinical evaluation. Here, we developed a pilot-scale production of FAKHRAVAC, a purified inactivated SARS-CoV-2 virus vaccine candidate that induces neutralizing antibodies in Balb/c mice, guinea pigs, rabbits, and non-human primates (Rhesus macaques—RM). After obtaining ethical code of IR.IUMS.REC.1399.566, immunizations of animals were conducted by using either of three different vaccine dilutions; High (H): 10 μg/dose, Medium (M): 5 μg/dose, and Low (L): 1 μg/dose, respectively. In the process of screening for viral seeds, viral strains that resulted in the most severe clinical manifestation in patients have been isolated for vaccine development. The viral seed produced the optimal immunity against SARS-CoV-2 virus, which suggests a possible broader neutralizing ability against SARS-CoV-2 strains. The seroconversion rate at the H-, M-, and L-dose groups of all tested animals reached 100% by 28 days after immunization. These data support the eligibility of FAKHRAVAC vaccine candidate for further evaluation in a clinical trial.